™
October 28, 2020 | Dallas, TX
Adaptive3D furthers its mission of providing materials to enable 21st century manufacturing by securing Series B financing from a syndicate led by the Arkema Group and bolstered by West Pharmaceutical Services, Clear Fir Partners, and current investors including Applied Ventures and the founding family of Texas Instruments.
Adaptive3D sells photopolymer resins to enable additive manufacturing of tough, strain-tolerant, tear-resistant rubbers, such as its flagship product, Elastic ToughRubber 90™: a tough, printable elastomer for all seasons. Adaptive3D printable photo-resins are optimized for high-throughput manufacturing of functional complex 3-dimensional plastic and rubber parts in consumer, healthcare, industrial, transportation and oil and gas markets. Arkema and West Pharmaceutical Services exemplify the potential end points of a complete additive manufacturing ecosystem, from new material development, scaled specialty resin manufacturing to functional end-use parts.
“Challenging the aging model of injection-molded rubbers and polyurethanes, Adaptive3D is now scaling production and distribution to deliver shelf-stable, print-stable, one-part photoresins that yield superior, manufactured end parts,” said President and CEO Walter Voit, PhD. “Our resins enable customers to topologically optimize and micro-architect their polymeric products to provide a sustainable competitive advantage now.”
“Arkema is a global leader in supplying specialty materials to enable sustainable, innovative solutions to manufacturing technologies,” said Sumeet Jain, the Senior Director of 3D Printing worldwide at Arkema. “Adaptive3D photoresins, based on Arkema materials and now validated in the market, further our customer-focused mission to reach into new application spaces with 21st century materials. Adaptive3D delivers compelling materials properties with an ease of printing and post processing—a great step forward for the whole additive manufacturing field.”
“At West, we see the potential of additive manufacturing to create differentiated, novel components and solutions for the healthcare sector,” said Scott Young, PhD, VP Research Innovation & Technology at West Pharmaceutical Services. “We understand well the challenges of commercializing new materials for the pharmaceutical packaging space, from innovation to validation to manufacturing at scale. We are impressed with the science and expertise at Adaptive3D. We are excited about their current and future engineered photo resins and look forward to working with Adaptive3D to push forward the technology boundaries of pharmaceutical packaging services.”
About Adaptive3D Technologies
Adaptive3D delivers premium polymer resins for additive manufacturing and specialty end applications. The company has a mission to enable high volume additive manufacturing through optimized materials. Adaptive3D offers leading additive manufacturing polymer resins and specialty polymers to a range of industries around the world in consumer, healthcare, industrial, transportation and oil and gas sectors. The company leads in printing and processing rubber-like materials, tough damping materials, and low-cure stress photopolymers. The deeply technical company has developed a patent portfolio based on fundamental materials processing, some of which has been translated from the University of Texas at Dallas and is based on the team’s past funding from the Defense Advanced Research Projects Agency, the Defense Threat Reduction Agency and the National Science Foundation.
About the Arkema Group
Building on its unique set of expertise in materials science, Arkema designs materials to address the ever-growing demand for innovative and sustainable materials, driven by the challenges of new energies, new technologies, the depletion of resources, mobility, and increasing urbanization. The Group is structured into three coherent and complementary segments dedicated to Specialty Materials (Adhesive Solutions, Advanced Materials, and Coating Solutions) accounting for some 80% of its sales, and an Intermediates segment leveraging competitive and global product lines. Sustained by the collective energy of its 20,500 employees and 144 production plants throughout the world, Arkema operates in some 55 countries and reports sales of €8.7 billion. Arkema fosters interaction with its stakeholders, and innovates around 6 solution-oriented research platforms: lightweight and designed materials, bio-based products, new energies, water management, electronics solutions, and home efficiency and insulation. These platforms shape the Group’s R&D to address the major global trends today and in the future.
For information, contact Zach Reagan at [email protected] or call 469-573-0024.